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MaCurrent algorithms for statin allocation in primary prevention use epidemiologic estimates of absolute risk. However,
a global risk prediction score has not been used as an enrollment criterion in any randomized trial of statin therapy.
Moreover, completed statin trials show greater relative risk reductions for those patients at lower levels of absolute risk.
Thus, risk calculators that rely solely on epidemiologic modeling do not ensure that those who will beneﬁt are selected
for treatment. We propose a hybrid approach to statin prescription for apparently healthy men and women that strongly
endorses pharmacologic treatment for those who have estimated 10-year risks$7.5% and for whom trial-based evidence
supports statin efﬁcacy in primary prevention. Although individuals could still be treated on the basis of absolute risk
alone, the hybrid approach is evidence-based, is easily applied in clinical practice, and may increase the transparency
of physician–patient interactions concerning prescription of statin therapy in primary prevention. (J Am Coll Cardiol
2015;65:942–8) © 2015 by the American College of Cardiology Foundation.D espite extensive randomized trial datademonstrating the efﬁcacy of statin ther-apy in primary prevention, there is contro-
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heart attacks and strokes. Current U.S. guidelines
for statin prescription are on the basis of epidemio-
logic estimates of 10-year risk and make the implicit
assumption that the greatest absolute risk reductions
will occur among those at the greatest absolute risk.
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943epidemiologic modeling. This is because no trial of
statin therapy has ever used a global risk prediction
score as an enrollment criterion. Worse, completed
statin trials contradict the premise that high absolute
risk always predicts greatest efﬁcacy; this issue is
already recognized in the ACC/AHA guidelines, where
it is correctly noted that 4 placebo-controlled trials
enrolled individuals with high absolute risk in the
settings of heart failure or renal failure, but found
little evidence of event reduction with statin therapy
despite large reductions in low-density lipoprotein
(LDL) cholesterol (5–8). Conversely, meta-analyses of
completed statin trials show statistically signiﬁcant
greater relative risk reductions for those at lower
levels of absolute risk than for those at higher risk
levels (9) (Figure 1). In addition, other than age, the
major determinants of high global risk are smoking
and hypertension, where the initial interventions
should be smoking cessation and blood pressure
reduction. Last, risk calculators that rely on epide-
miologic modeling in general populations, rather
than in those actually enrolled in clinical trials, do not
ensure that those selected for treatment are, in fact,
those who beneﬁt (3,10).
In an attempt to address these limitations, alter-
native approaches to statin allocation have been
proposed. One alternative eliminates the measure-
ment of risk factors, instead relying on thresholds of
age alone for statin prescription, a concept underly-
ing the “polypill” approach to prevention (11). A sec-
ond alternative seeks to address the core clinical
questions of “what works?” and “in whom?” on the
basis of completed randomized trials (12,13). As
opposed to the traditional risk-based approach usingFIGURE 1 Relative Risk Reductions per 1 mmol/l Reduction in LDL C
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Reductions are signiﬁcantly greater with statin therapy for patients at lo
(p ¼ 0.04 for trend test for heterogeneity). Data from Ridker (24). CI ¼epidemiologic modeling, this trial-based
approach seeks to match statin prescription
in primary prevention as closely as possible
to those individuals actually enrolled into the
extensive database of available clinical trials.
To date, estimates of the number of Ameri-
cans who might be treated using these alterna-
tive methods for statin allocation have not been
readily available. We addressed this issue using
data from the 2007 to 2010 National Health and
Nutrition Examination Survey (14) to derive estimates of
the number of middle-aged Americans who would be
recommended for statin therapy using the ACC/AHA
approach of drug prescription on the basis of calculated
10-year risks for hard atherosclerotic events. We then
derived similar estimates for the alternative approaches.
For the trial-based approach, we developed a statin
allocation algorithm on the basis of results of the 5 ran-
domized, double-blind, placebo-controlled trials of
statin therapy that were reported between 1995
and 2008, and which together comprise most of the
formal evidence base documenting the effectiveness
of statin therapy in primary prevention (15–19)
(Central Illustration, top). Details and methods under-
lying these analyses are provided in Online Table 1.
Our analyses suggest that 47.9 million of an esti-
mated 97.8 million American men and nonpregnant
women age 40 to 79 years and free of cardiovascular
disease would be recommended for consideration of
statin therapy on the basis of the “polypill” approach
of having diabetes or simply being $55 years of age. A
smaller number, 42.0 million, would be recom-
mended for consideration of statin therapy on the
basis of having diabetes or meeting the core entry
choleholesterol With Statin Therapy Compared With Control Patients
0.62 (0.47–0.81)
0.69 (0.60–0.79)
0.79 (0.74–0.85)
0.81 (0.77–0.86)
0.79 (0.74–0.84)
0.79 (0.77–0.81)
p<0.0001
0 0.75 1 1.25 1.50
atin/More Better Control/Less Better
RR (95%CI) Test for
Trend
(p=0.04)
χ2=4.291
w levels of absolute vascular risk than for those at higher levels
conﬁdence interval; LDL ¼ low-density lipoprotein; RR ¼ relative risk.
CENTRAL ILLUSTRATION Incorporating Trial Data Into a Hybrid Statin Algorithm for Primary Prevention
ALGORITHM FOR ALLOCATING STATIN THERAPY
Diabetes
LDL≥160
LDL≥130 HDL≤45
hsCRP≥2
Encourage
healthy
lifestyle
CARDS
WOSCOPS
MEGA
AFCAPS
TexCAPS 
JUPITER
Encourage
healthy
lifestyle
Middle aged men and women
free of cardiovascular disease
TRIAL
Y
N
N
N
N
N
Y
Y
Y Y
Initiate
statin
therapy
Age
Sex
Race
Total cholesterol
HDL cholesterol
Systolic BP
BP-treated
Diabetes
Smoker
70
Male
White
170
50
110
No
No
No
Risk-based recommendation:
Discuss use of moderate to 
high-intensity statin therapy
Trial-based Recommendation:
Would this patient have qualified 
for one of the pivotal statin trials 
that have proven efficacy?
Estimated 10-year risk
Modified Risk Calculator
No
13%
Age
Sex
Race
Total cholesterol
HDL cholesterol
Systolic BP
BP-treated
Diabetes
Smoker
50
Male
White
220
40
110
No
No
No
Risk-based recommendation:
Encourage healthy lifestyle
Trial-based Recommendation:
Would this patient have qualified 
for one of the pivotal statin trials 
that have proven efficacy?
Estimated 10-year risk
Modified Risk Calculator
Yes
4%
Ridker, P.M. et al. J Am Coll Cardiol. 2015; 65(9):942–8.
(Top) A trial-based algorithm for allocating statin therapy in primary prevention. Using a trial-based approach, statins would be allocated to
those meeting the fundamental entry criteria of the CARDS (Collaborative Atorvastatin Diabetes Study), WOSCOPS (West of Scotland Coronary
Prevention Study), MEGA (Management of Elevated cholesterol in the primary prevention Group of Adult Japanese study), AFCAPS/TexCAPS
(Air Force/Texas Coronary Atherosclerosis Prevention Study), and JUPITER (Justiﬁcation for Use of statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin). Thus, a trial-based approach guarantees that those prescribed statin therapy meet the inclusion criterion of at least 1
of the pivotal trials demonstrating that statin therapy in primary prevention reduces rates of myocardial infarction, stroke, and cardiovascular
revascularization procedures (see Online Appendix for details). (Bottom) A modiﬁed American College of Cardiology (ACC)/American Heart
Association (AHA) risk calculator. The proposed modiﬁed ACC/AHA risk calculator provides an estimate of 10-year risk and an indication as to
whether or not trial data exist for the participant of interest (see text for details). BP ¼ blood pressure; HDL ¼ high-density lipoprotein;
hsCRP ¼ high-sensitivity C-reactive protein (hsCRP); LDL ¼ low-density lipoprotein.
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FIGURE 2 Individuals Recommended for Statin Therapy
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Allocation By Calculated
ACC/AHA 10-year Risk
Allocation By Age
Thresholds Alone
Allocation By Trial Entry
Criteria and Age Thresholds
Each bar represents the number of Americans 40 to 79 years of age and currently free of
cardiovascular disease who would be recommended for treatment with statin therapy
in sensitivity analyses using the American College of Cardiology (ACC)/American Heart
Association (AHA) 10-year absolute risk approach (left), the age-alone approach as sug-
gested for the “polypill” (middle), and the trial entry criteria approach (right). Diabetic
subjects are included in all allocation schemes, and a range of age cutpoints from $45
through $60 years is shown. Salmon bars indicate the base case for each allocation
scheme (see Online Appendix for details).
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945criteria for at least 1 of the randomized trials that have
demonstrated statin efﬁcacy. In contrast, using cur-
rent ACC/AHA algorithms, 32.6 million Americans
would be recommended for consideration of statin
therapy on the basis of having diabetes or a calculated
10-year risk estimate of $7.5%. The number of in-
dividuals potentially eligible for statin therapy
ranged widely when we varied age thresholds for
treatment or varied levels of 10-year risk (Figure 2).
Unfortunately, our analyses also demonstrate that
reliance on any 1 of these approaches results either in
recommendations to consider treatment for in-
dividuals where trial data are lacking, recommenda-
tions to consider treatment for individuals at low
absolute risk, or both. As shown in the Venn diagram
(Figure 3), the traditional 10-year risk approach and
the formal evidence-based approach using trial data
identiﬁed substantially different groups of in-
dividuals for whom treatment would be considered.
For example, 11.1 million (34%) of those who would
be recommended to consider treatment using the
ACC/AHA 10-year risk cutpoint of $7.5% would not
have qualiﬁed for any of the major statin trials that
demonstrate efﬁcacy. This group includes many in-
dividuals with high absolute risk driven by hyper-
tension and smoking, conditions where ﬁrst-line
interventions should be smoking cessation and blood
pressure reduction; calculated risk for such in-
dividuals would be substantially lower if these in-
terventions were successful. Furthermore, 28.5% of
this group (3.2 million) had no major modiﬁable risk
factors, and yet had 10-year risk estimates calling for
statin therapy simply due to older age. Conversely,
20.6 million (49%) of those who would be recom-
mended to consider treatment using the trial-based
approach had estimated 10-year risks below 7.5%.
This group tended to include younger individuals,
women, and those with isolated elevations of high-
sensitivity C-reactive protein (hsCRP) or LDL (Online
Table 2). The proportion treated according to the 3
strategies was also very different by age (Figure 4).
The risk-based approach would initiate a discussion
of statin therapy for all individuals older than 70
years of age (66 years of age for men), whereas the
age-based approach would treat everyone above 55
years of age. The trial-based approach is less age-
dependent because it is on the basis of individual
risk factors.
We believe a hybrid approach that minimizes these
limitations merits serious consideration by the ACC
and AHA as these organizations develop new treat-
ment guidelines. A hybrid approach represents a
statin allocation strategy that conservatively com-
bines aspects of the risk- and trial-based approachesto deﬁne a population who clearly should be treated.
Speciﬁcally, the hybrid approach would strongly
endorse statin therapy in primary prevention for
those in the intersection of the Venn diagram in
Figure 3, that is, the 21.4 million middle-aged Amer-
icans who have estimated 10-year risks $7.5% and for
whom there is clear trial-based evidence of statin
efﬁcacy in primary prevention.
There are potential advantages to this proposal.
Most importantly, the hybrid approach provides
transparency and avoids the pitfalls inherent in the
current absolute-risk system used to allocate statin
therapy that result in recommendations both to
consider treating some individuals where trial data
are lacking and to withhold treatment from others
where trials have demonstrated efﬁcacy. For
example, the current 10-year risk approach results in
recommendations to consider treatment for a sub-
stantive number of individuals (3.2 million) with no
modiﬁable risk factors, yet who are calculated to be at
high absolute risk due to older age alone. In part to
avoid this problem, the ACC/AHA guidelines suggest
the use of secondary criteria such as family history,
FIGURE 3 Venn Diagrams Illustrating the Hybrid Approach to Statin Allocation:
Base Case
ACC/AHA 10-year Risk ≥ 7.5% Randomized Trial Entry Criteria
32.6 11.1 21.4 20.6 42.0
Venn diagram comparing the 10-year absolute risk approach with the trial entry criteria
approach for allocation of statin therapy in primary prevention. As shown, 32.6 million
Americans would be recommended for statin treatment using the ACC/AHA 10-year risk
criteria of >7.5% (light blue circle, left), whereas 42.0 million Americans would be rec-
ommended for statin therapy using the base case randomized trial entry criteria (medium
blue circle, right). The intersection of these 2 approaches indicates that 21.4 million in-
dividuals have both a calculated 10-year risk >7.5% and would have qualiﬁed for at least 1
of the major statin trials demonstrating efﬁcacy (dark blue, middle). Abbreviations as in
Figure 2.
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946coronary artery calcium, hsCRP, or the ankle-brachial
index in these settings (1,2). However, in contrast to
the JUPITER (Justiﬁcation for Use of statins in Pre-
vention: an Intervention Trial Evaluating Rosuvasta-
tin) trial data for hsCRP (19), there are no prospective,
randomized trial data to support the use of coronary
artery calciﬁcation, family history, or ankle-brachial
index as a method to allocate statin therapy.f Age on Treatment Decisions
50-54 55-59 60-64 65-69 70-74 75-79
% ≥7.5% risk
% Trial-based
% Age-based
s of the National Health and Nutrition Examination Survey population
ial-, and age-based criteria. Data are presented across a full range of
years.An additional advantage of our proposed hybrid
approach might be increased utilization of statins
among those physicians who have voiced concern
about the net beneﬁt to risk ratio of statin therapy in
primary prevention, a clinically-relevant issue given
the small, but statistically signiﬁcant, increases in
rates of muscle injury and diabetes in this setting
(20,21). For such physicians, the combined approach
outlined here avoids the perception of recommending
statin therapy in settings such as heart failure or renal
failure, where absolute risk is high, yet statin therapy
has not proven effective at lowering event rates
despite substantial LDL reduction (4–7). This
approach is consistent with current ACC/AHA rec-
ommendations, but the current risk calculator does
not make this explicit. The hybrid approach further
avoids the problem faced in 10-year risk approaches,
where statin allocation is inadvertently driven by
hypertension and cigarette consumption, for which
the initial interventions are blood pressure reduction
and smoking cessation, respectively. The combined
approach also avoids inadvertent recommendations
to treat those at high risk simply due to older age. Of
interest, because it takes into account both the pa-
tient’s individual absolute risk and evidence-based
treatment effects for patient groups found to have a
beneﬁt, the combined approach comes close to that of
using individualized treatment effects (22).
Critics may argue that a hybrid approach is too
complicated to implement. We strongly disagree. All
that is required to bring this hybrid approach into
clinical practice is the addition of a single new output
on the current ACC/AHA website for risk prediction
stating whether or not the patient of interest would
have qualiﬁed for 1 of the pivotal statin trials
demonstrating efﬁcacy in primary prevention. A
simple yes or no answer, using the ﬂow diagram in
the Central Illustration, would let the responsible
physician know immediately if there is hard trial ev-
idence to support prescription for the patient under
consideration.
We note that a change in the 10-year risk threshold
(for the absolute risk approach) or a change in the age
threshold (for the trial-based approach) will not
effectively substitute for the hybrid approach pro-
posed here. Figure 5 presents Venn diagrams for
sensitivity analyses comparing the 10-year risk
approach to the randomized trial approach. As
shown, in all instances, the 10-year absolute risk
approach to statin allocation continued to result
in recommendations to consider treatment for
many individuals for whom trial data are lacking.
Similarly, in all instances, the clinical trial criteria
approach continued to result in recommendations to
FIGURE 5 Sensitivity Analyses for the Hybrid Approach
Trial
Entry
Criteria
+ Age ≥ 45
Trial
Entry
Criteria
+ Age ≥ 50
Trial
Entry
Criteria
+ Age ≥ 55
Trial
Entry
Criteria
+ Age ≥ 60
ACC/AHA 10-year Risk ≥ 5% ACC/AHA 10-year Risk ≥ 7.5% ACC/AHA 10-year Risk ≥ 10%
17.0 27.3 14.8
18.8 25.5 8.7
21.5 22.8 4.0
24.9 19.3 1.6 14.7 17.8 3.2
13.1 19.5 7.3
11.7 20.9 13.4
11.1 21.4 20.6 8.0 18.3 23.7
8.2 18.1 16.2
8.8 17.5 9.3
10.0 16.3 4.6
Venn diagrams for sensitivity analysis comparing the current ACC/AHA 10-year risk approach for various levels of risk (light blue) with the trial
entry criteria approach for various age thresholds (medium blue), as well as the intersection inclusive of both approaches (dark blue). As
shown, regardless of the scenario chosen, the number recommended for statin therapy using the hybrid approach (at the intersections of the
Venn diagrams) does not vary widely. Abbreviations as in Figure 2.
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947consider treatment for many individuals because
the absolute risk was low. This trend toward po-
tential under-treatment of those where trial data
indicate efﬁcacy and potential overtreatment of
those where trial data are lacking (using the 10-year
risk-based approach), or potential overtreatment
where absolute risk was low (using the trial-based
approach), is a consistent ﬁnding that cannot be
eliminated by increasing or decreasing the 10-year
thresholds of risk. However, as also shown in the
Venn diagrams of Figure 5, the number of in-
dividuals in the intersections (reﬂecting the pro-
posed hybrid allocation approach) does not vary
widely. For example, in sensitivity analyses for the
10-year risk threshold of $7.5%, the number of in-
dividuals in the intersection who additionallyfulﬁlled trial-based criteria varied between 17.8
million and 21.4 million.
The bottom of the Central Illustration presents ex-
amples of how the hybrid proposal would work in
daily practice using a modiﬁed ACC/AHA risk cal-
culator as a smartphone application. As shown on
the left, a healthy, white, 70-year-old male with
“optimal” risk factors (total cholesterol 170 mg/dl,
high-density lipoprotein cholesterol 50 mg/dl, un-
treated systolic blood pressure 110 mm Hg, non-
smoker, no diabetes) is nonetheless found to have a
10-year estimated risk of 13% according to the cur-
rent ACC/AHA prediction algorithm. However, this
man would not have qualiﬁed for randomization
into any of the clinical trials that demonstrate statin
efﬁcacy in primary prevention, a fact made fully
Ridker et al. J A C C V O L . 6 5 , N O . 9 , 2 0 1 5
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948transparent by the modiﬁed ACC/AHA calculator. In
contrast, as shown on the right, a hyperlipidemic,
white, 50-year-old male would have qualiﬁed for
multiple pivotal statin trials, but is found to have an
ACC/AHA estimated 10-year risk of only 4%.
We are hopeful that the ACC/AHA will recalibrate
the existing pooled risk calculator to avoid over-
estimation of 10-year risk and consider adding the
simple “yes/no” question concerning trial eligibility.
It is not our intent to suggest that following the hybrid
approach is necessarily the best way to prescribe
statin therapy in primary prevention, and we recog-
nize that this approach has not been subject to
randomization. Furthermore, as recently described(23), randomized trials also have substantive limita-
tions and may not accurately address all patient needs
in the community. We do believe, however, that a risk
calculator providing both a 10-year risk estimate and a
statement related to trial eligibility has the potential
to improve care by increasing the transparency of
physician–patient interactions concerning the pre-
scription of statin therapy in primary prevention.
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